In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Comparison of left ventricular function changes in inflammatory and non-inflammatory dilated cardiomyopathy in the time course

Session Poster Session 2

Speaker Associate Professor Jan Krejci

Congress : Heart Failure 2019

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Myocarditis
  • Session type : Poster Session
  • FP Number : P1140

Authors : J Krejci (Brno,CZ), P Hude (Brno,CZ), H Poloczkova (Brno,CZ), E Ozabalova (Brno,CZ), J Godava (Brno,CZ), T Honek (Brno,CZ), V Zampachova (Brno,CZ), I Svobodova (Brno,CZ), J Jarkovsky (Brno,CZ), K Benesova (Brno,CZ), L Spinarova (Brno,CZ)

Authors:
J Krejci1 , P Hude1 , H Poloczkova1 , E Ozabalova1 , J Godava1 , T Honek1 , V Zampachova1 , I Svobodova1 , J Jarkovsky2 , K Benesova2 , L Spinarova1 , 1St. Anne´s University Hospital, Masaryk University - Brno - Czechia , 2Institute of Biostatistics and Analyses of Masaryk University - Brno - Czechia ,

Citation:

Introduction: In patients with newly diagnosed left ventricle (LV) dysfunction of non-ischemic etiology there is a considerable chance of recovery of LV function. It is known that the presence of myocarditis increases the chance of improving the left ventricle ejection fraction (LVEF) in comparison with patients without evidence of myocardial inflammation.

Purpose: To evaluate the differences in LVEF changes between inflammatory cardiomyopathy (ICM) and non-inflammatory dilated cardiomyopathy (DCM) groups in different time periods during the first year after the diagnosis was established.

Patient and methods: DCM group: 126 patients, 79% men and 21% women, mean age 48.6 ± 10.4 years, symptoms duration to diagnosis 2.9 ± 2.6 months. ICM group: 86 patients, 77% men and 23% women (p = 0.74 for the difference between groups), mean age 44.5 ± 12.6 years (p = 0.02), symptoms duration 2.3 ± 2.2 months (p = 0.07).

Results: In the DCM group, the baseline LVEF was 23.9 ± 7.0%, in the ICM group 24.3 ± 7.2% (p = 0.77). In the 12-month follow-up, LVEF in DCM group improved to 31.3 ± 10.3% (p ? 0.001), in ICM group to 41.1 ± 12.1% (p ? 0.001), the difference between the groups was 7.4 ± 9.9% (DCM) vs 16.8 ± 13.4% (ICM; p ? 0.001). In the first 3 months, LVEF increased by 3.9 ± 8.1% (DCM) vs 11.4 ± 9.7% (ICM; p ? 0.001), between the 3rd and 6th month by 2.0 ± 5.6% (DCM) vs. 3.8 ± 7.3% (ICM; p = 0.08) and between 6th and 12th month by 1.5 ± 6.7% (DCM) vs. 1.6 ± 7.3% (ICM; p = 0.63).

Conclusion: Although the improvement of LVEF in the ICM group was more pronounced  throughout the first year after diagnosis in comparison to DCM group, statistical significance of the difference between the two groups was achieved only within the first 3 months after the diagnosis was established.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are